Bimagrumab: Community Protocols & Reports
Aggregated community experiences, protocols, and stacking patterns
Community-Sourced Information
The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.
For peer-reviewed dosing protocols, see the clinical dosing guide.
Browse community protocols for all 130 peptides →
📌TL;DR
- •2 community protocols documented
- •Evidence level: Anecdotal Reports
- •Based on 40 community reports
- •2 stacking patterns reported
Clinical vs. Community Protocol Differences
How community-reported protocols differ from clinical research protocols.
| Aspect | Clinical Approach | Community Approach | Significance |
|---|---|---|---|
| Availability | Bimagrumab is currently in Phase 2 clinical trials (Eli Lilly acquired it via Versanis Bio acquisition for up to $1.925 billion). It is administered by IV infusion in clinical settings. | Community interest is very high, particularly from fitness and weight management communities, due to the unique ability to lose fat and gain muscle simultaneously. However, bimagrumab is not available outside clinical trials and cannot be sourced from research peptide suppliers. | high As a monoclonal antibody, bimagrumab requires pharmaceutical-grade manufacturing and IV administration. Community interest significantly exceeds availability. |
| Body Composition Effects | Phase 2 trials showed 20.5% reduction in fat mass with 3.6% gain in lean mass as monotherapy. The BELIEVE trial with semaglutide showed 22.1% weight loss with 92.8% of loss from fat mass and 67% greater lean mass preservation vs semaglutide alone. | Fitness and bodybuilding communities are particularly excited about the recomposition effect (simultaneous fat loss and muscle gain), which is difficult to achieve with diet and exercise alone. Community discussions frequently compare bimagrumab favorably to anabolic steroids for body composition improvement. | moderate The clinical data is genuinely impressive for body composition. However, community comparisons to anabolic steroids are not well-founded, as the mechanisms and magnitude of muscle gain differ significantly. |
Compare these community approaches with published research findings.
Community Protocols
BELIEVE Phase 2b Trial Protocol
Niche- Route
- Intravenous infusion
- Dose
- 10 mg/kg
- Frequency
- Every 4 weeks
- Duration
- 48 weeks (trial duration)
Clinical trial protocol combined with semaglutide 2.4 mg weekly; not yet commercially available
Phase 2 Obesity Monotherapy Protocol
Niche- Route
- Intravenous infusion
- Dose
- 10 mg/kg
- Frequency
- Every 4 weeks
- Duration
- 48 weeks
Demonstrated 20.5% fat loss with 3.6% lean mass gain in type 2 diabetes and obesity
Stacking Patterns
Bimagrumab + Semaglutide (BELIEVE Protocol)
NicheCombination therapy for enhanced weight loss with lean mass preservation; the BELIEVE trial showed this combination achieves superior body composition outcomes compared to either agent alone
Bimagrumab + GLP-1 RA (Theoretical)
NicheTheoretical combination of myostatin pathway inhibition with GLP-1 mediated weight loss; community-discussed but not yet tested in trials
Check stack compatibility and review potential side effects before combining peptides.
Unlock community dosing protocols and stacking combos
See the exact doses, routes, and schedules 40+ self-experimenters report. Free with email.
150+ peptide profiles · 30+ comparisons · 18 research tools
Sources
- Reddit r/Peptides|Bimagrumab muscle and fat discussion threads(accessed 2026-02-16)
- Reddit r/loseit|Bimagrumab and semaglutide combination weight loss discussions(accessed 2026-02-16)
- WellFounded Health|Can a Muscle-Building Antibody Transform Weight Loss?(accessed 2026-02-16)
- STAT News|New Eli Lilly drug could help prevent muscle loss while taking a GLP-1(accessed 2026-02-16)
- RP Strength|Cardio in a Shot? The New Drugs That Build Muscle and Burn Fat(accessed 2026-02-16)
Community Evidence Overview#
This page presents aggregated community discussions and context for bimagrumab (BYM338). This is not clinical evidence and should not be used as medical guidance.
Bimagrumab has generated significant community interest, particularly following the BELIEVE trial results showing impressive body recomposition when combined with semaglutide. Community discussion is concentrated in fitness, weight management, and longevity communities, though the drug is not yet available outside clinical trials.
Why the Community Interest#
Bimagrumab's unique appeal is its ability to achieve what most interventions cannot: simultaneous fat loss and lean mass gain. Key clinical findings that drive community discussion:
- Monotherapy: 20.5% fat mass reduction with 3.6% lean mass gain over 48 weeks
- Combination with semaglutide: 22.1% total weight loss with 92.8% from fat mass
- Lean mass preservation: 67% greater lean mass preservation vs semaglutide alone
These results address the major limitation of GLP-1 receptor agonist weight loss -- that approximately 30-40% of weight lost is typically lean mass.
Availability and Access#
Bimagrumab is not available outside clinical trials. It was acquired by Eli Lilly through the $1.925 billion purchase of Versanis Bio and is in Phase 2 development. As a monoclonal antibody requiring IV infusion, it cannot be self-administered and is not available from research peptide suppliers.
Community Speculation#
Community discussions frequently speculate about pricing, eligibility criteria, and potential off-label use once approved. Comparisons to the GLP-1 RA market suggest significant commercial potential, though access and affordability remain uncertain.
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles · 30+ comparisons · 18 research tools
Frequently Asked Questions About Bimagrumab
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.